NADAC acquisition cost data for PERSERIS ER 90 MG POWDER SYRNG. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 12496009002 | $1,879.84 | 2022-07-20 | Rx |
| 12496009002 | $1,879.84 | 2022-07-20 | Rx |
| 12496009002 | $1,879.84 | 2022-07-20 | Rx |
| 12496009002 | $1,879.84 | 2022-07-20 | Rx |
| 12496009002 | $1,879.84 | 2022-07-20 | Rx |
| 12496009002 | $1,879.84 | 2022-07-20 | Rx |
| 12496009002 | $1,879.84 | 2022-07-20 | Rx |
| 12496009002 | $1,879.84 | 2022-07-20 | Rx |
| 12496009002 | $1,879.84 | 2022-07-20 | Rx |
| 12496009002 | $1,879.84 | 2022-07-20 | Rx |
Generic: Risperidone | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $4.7M | 2,206 | 644 | $2,112.66 |
| 2020 | $12.3M | 5,472 | 904 | $2,250.33 |
| 2021 | $15.9M | 6,620 | 1,093 | $2,406.31 |
| 2022 | $25.0M | 9,813 | 1,813 | $2,545.07 |
| 2023 | $42.8M | 15,827 | 2,832 | $2,690.71 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $3.8M | 1,371 | 243 |
| Ohio | $3.8M | 1,425 | 259 |
| Texas | $3.7M | 1,374 | 258 |
| Florida | $2.5M | 933 | 179 |
| Missouri | $2.2M | 808 | 118 |
| North Carolina | $2.1M | 778 | 115 |
| New York | $2.0M | 757 | 128 |
| Louisiana | $2.0M | 708 | 175 |
| Oklahoma | $1.9M | 675 | 137 |
| Arizona | $1.8M | 693 | 144 |
| Indiana | $1.6M | 604 | 92 |
| Georgia | $1.4M | 511 | 98 |
| South Carolina | $1.2M | 443 | 61 |
| Tennessee | $1.2M | 430 | 85 |
| Michigan | $1.2M | 449 | 85 |
| Illinois | $940.7K | 335 | 64 |
| New Jersey | $921.0K | 330 | 68 |
| Wisconsin | $877.2K | 320 | 56 |
| Pennsylvania | $811.9K | 315 | 59 |
| Kansas | $685.8K | 251 | 38 |
| Alabama | $656.1K | 246 | 54 |
| Kentucky | $622.2K | 234 | 47 |
| Hawaii | $617.0K | 228 | 41 |
| Mississippi | $469.3K | 170 | 45 |
| Iowa | $452.1K | 164 | 36 |
| Maryland | $276.4K | 100 | 23 |
| Idaho | $268.3K | 98 | 20 |
| Virginia | $263.1K | 108 | 23 |
| Utah | $242.9K | 88 | 13 |
| Virgin Islands | $213.1K | 80 | 11 |
| Massachusetts | $204.8K | 86 | 11 |
| West Virginia | $202.5K | 68 | 14 |
| Delaware | $183.0K | 73 | 17 |
| Oregon | $172.5K | 60 | N/A |
| Minnesota | $159.7K | 60 | N/A |
| Nevada | $158.9K | 56 | 16 |
| Colorado | $139.9K | 53 | 11 |
| Washington | $131.0K | 49 | 16 |
| Montana | $109.0K | 39 | N/A |
| Arkansas | $100.6K | 38 | N/A |
| District of Columbia | $99.1K | 40 | N/A |
| Rhode Island | $85.3K | 34 | N/A |
| Connecticut | $76.0K | 30 | N/A |
| Nebraska | $72.2K | 30 | N/A |
| South Dakota | $44.2K | 19 | N/A |
| Maine | $41.5K | 18 | N/A |
| New Hampshire | $40.2K | 14 | N/A |
| Alaska | $24.2K | 11 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.